CORV - Correvio Pharma Corp.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.4199
0.0000 (0.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.4199
Open0.4160
Bid0.4160 x 1200
Ask0.4199 x 1400
Day's Range0.4160 - 0.4200
52 Week Range0.2100 - 2.7900
Volume3,759,129
Avg. Volume3,858,307
Market Cap27.794M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.75
  • Correvio Obtains Final Order for Plan of Arrangement
    PR Newswire

    Correvio Obtains Final Order for Plan of Arrangement

    Correvio Pharma Corp. ("Correvio" or the "Company") (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that it has obtained a final order from the Supreme Court of British Columbia approving the previously announced plan of arrangement (the "Arrangement") with ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA") pursuant to which ADVANZ PHARMA, through its wholly-owned subsidiary Mercury Pharma Group Limited ("Mercury"), has agreed to acquire all of the issued and outstanding shares of Correvio for a total purchase price of approximately US$76 million, which includes the repayment of certain Correvio indebtedness, as described in Correvio's information circular dated April 16, 2020.

  • Correvio Announces Results from Annual General and Special Meeting of Securityholders
    CNW Group

    Correvio Announces Results from Annual General and Special Meeting of Securityholders

    VANCOUVER , May 15, 2020 /CNW/ - Correvio Pharma Corp. ("Correvio" or the "Company") (CORV) (CORV), today announced the results of voting on matters considered at its annual general and special meeting (the "Meeting") of Correvio shareholders and holders of options, restricted share units and phantom share units (collectively, the "Securityholders") which took place in a virtual format earlier today. At the Meeting, Securityholders were asked to, among other things, pass a special resolution relating to the proposed plan of arrangement (the "Arrangement"), involving the Company and a subsidiary of ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA").

  • Will Correvio Pharma (CORV) Report Negative Q1 Earnings? What You Should Know
    Zacks

    Will Correvio Pharma (CORV) Report Negative Q1 Earnings? What You Should Know

    Correvio (CORV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Leading Independent Proxy Advisory Firm Glass Lewis Recommends That Correvio Shareholders Vote for the Arrangement With ADVANZ PHARMA
    CNW Group

    Leading Independent Proxy Advisory Firm Glass Lewis Recommends That Correvio Shareholders Vote for the Arrangement With ADVANZ PHARMA

    VANCOUVER , May 6, 2020 /CNW/ - Correvio Pharma Corp. ("Correvio" or the "Company") (CORV) (CORV), today announced that Glass, Lewis & Co., LLC ("Glass Lewis"), a leading independent proxy advisory firm, released a report (the "Glass Lewis Report") recommending that Correvio shareholders vote in favor of the proposed plan of arrangement (the "Arrangement") with ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA"). The Arrangement will be executed through a wholly-owned subsidiary of ADVANZ PHARMA.

  • Correvio Announces Postponement of Its First Quarter 2020 Financial Results Due to Impacts From COVID-19
    PR Newswire

    Correvio Announces Postponement of Its First Quarter 2020 Financial Results Due to Impacts From COVID-19

    Correvio Pharma Corp. ("Correvio" or the "Company") (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that it has postponed the reporting of its financial statements and management discussion and analysis (the "2020 Disclosure") in respect of the first quarter ended March 31, 2020 beyond the previous expected date of May 15, 2020. The Company now expects to release its 2020 Disclosure on or before June 29, 2020, subject to the Company ceasing to be a reporting issuer prior to the filing deadline as a result of the Proposed Arrangement (as defined below).

  • Leading Independent Proxy Advisory Firm ISS Recommends That Correvio Shareholders Vote for the Arrangement with ADVANZ PHARMA
    CNW Group

    Leading Independent Proxy Advisory Firm ISS Recommends That Correvio Shareholders Vote for the Arrangement with ADVANZ PHARMA

    VANCOUVER , May 1, 2020 /CNW/ - Correvio Pharma Corp. ("Correvio" or the "Company") (CORV) (CORV), today announced that Institutional Shareholder Services Inc. ("ISS"), a leading independent proxy advisory firm, released a report (the "ISS Report") recommending that Correvio shareholders vote in favor of the proposed plan of arrangement (the "Arrangement") with ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA"). The Arrangement will be executed through a wholly-owned subsidiary of ADVANZ PHARMA.

  • SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Mergers; Are Shareholders Getting a Fair Deal?
    PR Newswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Mergers; Are Shareholders Getting a Fair Deal?

    Halper Sadeh LLP, a global investor rights law firm, continues to investigate whether the following proposed mergers are fair to shareholders. Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders:

  • Correvio Obtains Interim Order For Plan Of Arrangement
    CNW Group

    Correvio Obtains Interim Order For Plan Of Arrangement

    VANCOUVER , April 8, 2020 /CNW/ - Correvio Pharma Corp. ("Correvio" or the "Company") (CORV) (CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced  that it has obtained an interim order from the Supreme Court of British Columbia (the "Court") authorizing the holding of an annual general and special meeting (the "Meeting") of the Securityholders (as defined below) and matters relating to the conduct of the Meeting. At the Meeting, shareholders and holders of options, restricted share units and phantom share units (collectively, the "Securityholders") will be asked to, among other things, pass a special resolution relating to the proposed plan of arrangement (the "Arrangement"), involving the Company and a subsidiary of ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA").

  • Correvio Reports Full Year 2019 Financial Results
    PR Newswire

    Correvio Reports Full Year 2019 Financial Results

    Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today reported financial results for the full year ended December 31, 2019 and commented on recent accomplishments and plans.

  • GlobeNewswire

    Are Shareholders Getting a Fair Deal? Halper Sadeh LLP Investigates the Sale of These Companies – CORV, TERP, IOTS, CBB

    NEW YORK, March 24, 2020 -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate whether the following proposed mergers are fair to shareholders..

  • CORREVIO PHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Correvio Pharma Corp. - CORV
    Business Wire

    CORREVIO PHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Correvio Pharma Corp. - CORV

    Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Correvio Pharma Corp. (NasdaqGS: CORV) to ADVANZ PHARMA Corp. Limited. Under the terms of the proposed transaction, shareholders of Correvio will receive only $0.42 in cash for each share of Correvio that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

  • ACCESSWIRE

    Are Shareholders Getting a Fair Deal? Halper Sadeh LLP Investigates the Sale of These Companies - TTPH, CORV

    Are Shareholders Getting a Fair Deal? Halper Sadeh LLP Investigates the Sale of These Companies - TTPH, CORV NEW YORK, NY / ACCESSWIRE / March 16, 2020 / Halper Sadeh LLP, a global investor rights law ...

  • ADVANZ PHARMA to Acquire Correvio
    PR Newswire

    ADVANZ PHARMA to Acquire Correvio

    Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today announced its entry into an arrangement agreement ("Arrangement Agreement") dated March 15, 2020, for ADVANZ PHARMA Corp. Limited ("ADVANZ PHARMA", TSX:ADVZ) to acquire all of the issued and outstanding shares of Correvio. The acquisition, which will be executed through ADVANZ PHARMA's wholly-owned subsidiary Mercury Pharma Group Limited ("Mercury"), is expected to have a total purchase price of approximately US$76 million, which includes the repayment of certain Correvio indebtedness, pursuant to a plan of arrangement under the Canada Business Corporations Act (the "Arrangement").

  • Benzinga

    Benzinga Pro's Top 5 Stocks To Watch For Tues., Mar. 10, 2020: FXI, TSLA, OXY, CORV, CLDR

    Benzinga Pro's Stocks To Watch For Tuesday * iShares China Large-Cap ETF (FXI) \- The most-active ETF reflecting price action in the broader Chinese markets, the FXI was up more than 3% in pre-market action. A Global Times report suggested the last patient was discharged from the Wuchang makeshift hospital in Wuhan on Tuesday. Additionally, Chinese President Xi declared victory over the coronavirus in the city of Wuhan. US futures were up about 4% and hit a limit up circuit breaker -- the opposite of what happened in pre-market action Monday morning. * Tesla (TSLA) \- The stock was up about 9% to over the $650 level. A report suggested Tesla plans to increase production capacity for certain parts at its Shanghai factory. * Occidental Petroleum (OXY) \- One of the hardest hit oil & gas stocks Monday amid the massive drop in crude oil prices, Occidental shares rebounded Tuesday. After the stock fell more than 50% on Monday, shares were up 23% Tuesday morning. More than 103 million shares were traded on Monday, compared to the stock's average daily volume of just 13 million shares. * Correvio Pharma (CORV) \- Shares were up 30% following news of a partnership with Hong Kong Teson Pharma Limited for an exclusive agreement for the commercialization of Aggrastat® for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome. * Cloudera (CLDR) \- Will report Q4 results after the market close on Tuesday. Analysts expect a loss of about $0.03/share on sales of about $202 million.See more from Benzinga * Benzinga Pro's Top 5 Stocks To Watch For Mon., Mar. 9, 2020: XOM, GLD, BA, TSLA, SPEX * Benzinga Pro's Top 5 Stocks To Watch For Tues., Feb. 18, 2020: AAPL, WMT, TSLA, FLR, SPWR * Benzinga Pro's Top 5 Stocks To Watch For Fri., Feb. 14, 2020: TSLA, ROKU, CRON, YELP, AMD(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Correvio Partners with Hong Kong Teson Pharma Limited for the Commercialization of Aggrastat® in China
    PR Newswire

    Correvio Partners with Hong Kong Teson Pharma Limited for the Commercialization of Aggrastat® in China

    Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, and Hong Kong Teson Pharma Limited (Teson), a privately-held pharmaceutical company, today announced that Correvio International Sàrl, a wholly owned subsidiary of Correvio, and Teson have entered into an exclusive agreement for the commercialization of Aggrastat® (tirofiban hydrochloride). The agreement covers the territories of mainland China (excluding Taiwan and Hong Kong) and Macau. Aggrastat® is Correvio's marketed asset for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).

  • When Can We Expect A Profit From Correvio Pharma Corp. (TSE:CORV)?
    Simply Wall St.

    When Can We Expect A Profit From Correvio Pharma Corp. (TSE:CORV)?

    Correvio Pharma Corp.'s (TSE:CORV): Correvio Pharma Corp., a specialty pharmaceutical company, engages in developing...

  • Correvio Responds to Market Activity
    CNW Group

    Correvio Responds to Market Activity

    VANCOUVER , March 2, 2020 /CNW/ - At the request of Investment Industry Regulatory Organization of Canada ("IIROC"), Correvio Pharma Corp. (CORV) (CORV) (the "Company") wishes to confirm that it is not aware of any material, undisclosed information related to the Company that would account for the recent increase in the market price and level of trading volume of its common shares. As announced on December 11, 2019 , the Company is engaged in a process to explore strategic options to maximize stakeholder value which is ongoing.

  • FINAL DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Correvio Pharma Corp. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
    ACCESSWIRE

    FINAL DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Correvio Pharma Corp. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / February 10, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Correvio Pharma Corp. ("Correvio" or "the Company") (NASDAQ:CORV) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between October 23, 2018 and December 5, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before February 10, 2020. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

  • GlobeNewswire

    INVESTOR ALERT - Correvio Pharma Corp. (CORV) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Plaintiff Deadline: February 10, 2020

    This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) the data supporting the Resubmitted New Drug Application ("NDA") for Brinavess did not minimize the significant health and safety issues observed in connection with the drug's original NDA; (2) the foregoing substantially diminished the likelihood that the U.S. Food and Drug Administration would approve the Resubmitted NDA; and (3) as a result, Correvio's public statements were materially false and misleading at all relevant times.

  • ACCESSWIRE

    CORV FINAL DEADLINE: ROSEN, INVESTOR COUNSEL, Reminds Correvio Pharma Corp. Investors of Important February 10 Deadline in Securities Class Action

    NEW YORK, NY / ACCESSWIRE / February 8, 2020 / Rosen Law Firm reminds purchasers of the securities of Correvio Pharma Corp. between October 23, 2018 and December 5, 2019, inclusive (the "Class Period") ...

  • FINAL DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Correvio Pharma Corp. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
    ACCESSWIRE

    FINAL DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Correvio Pharma Corp. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / February 7, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Correvio Pharma Corp. ("Correvio" or "the Company") (NASDAQ:CORV) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between October 23, 2018 and December 5, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before February 10, 2020. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

  • ACCESSWIRE

    FINAL DEADLINE FEBRUARY 10: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Correvio Pharma Corp. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / February 6, 2020 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Correvio Pharma Corp. ("Correvio" ...

  • GlobeNewswire

    SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Correvio Pharma Corporation of Class Action Lawsuit and Upcoming Deadline – CORV

    Pomerantz LLP announces that a class action lawsuit has been filed against Correvio Pharma Corporation (“Correvio” or the “Company”) (NASDAQ: CORV) and certain of its officers. The class action, filed in United States District Court, for the Southern District of New York, and docketed under 19-cv-11361, is on behalf of a class consisting of investors who purchased or otherwise acquired Correvio securities between October 23, 2018 and December 5, 2019, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

  • GlobeNewswire

    Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Correvio Pharma Corporation

    If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Charles Linehan, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. On December 6, 2019, U.S. Food and Drug Administration (“FDA”) staffers who reviewed the Company’s resubmitted New Drug Application (“NDA”) for Brinavess found that the drug’s benefits did not offset its risks because Brinavess was associated with “serious liabilities” including irregular heartbeat, low blood pressure, and death.

  • 5-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Correvio Pharma Corp. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
    ACCESSWIRE

    5-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Correvio Pharma Corp. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / February 5, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Correvio Pharma Corp. ("Correvio" or "the Company") (NASDAQ:CORV) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 23, 2018 and December 5, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before February 10, 2020.